Sellas Life Sciences Stock Discussion

$Sellas Life Sciences(SLS.US)$ Reuters· 1 min ago
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Sls009 for the Treatment of Pediatric Acute Myeloid Leukemia

$Sellas Life Sciences(SLS.US)$  lets go! great news

$Sellas Life Sciences(SLS.US)$ Junk stock that hasn't gone up a bit and has been in a downward spiral.

$Sellas Life Sciences(SLS.US)$ Fuck you, it's a crap stock.

$Sellas Life Sciences(SLS.US)$ SELLAS Life Sciences Granted Orphan Drug Designation By European Commission For SLS009, A Novel CDK9 Inhibitor For Treating Acute Myeloid Leukemia

$Sellas Life Sciences(SLS.US)$
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
SELLAS Life Sciences Group announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for SLS009, a selective CDK9 inhibitor, for treating acute myeloid leukemia (AML).
This designation follows positive preliminary Phase 2 data and aligns with the previous FDA ODD. The designation provides financial and regul...

$Sellas Life Sciences(SLS.US)$
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
SELLAS Life Sciences has received Rare Pediatric Disease Designation (RPDD) from the FDA for its drug SLS009, targeting pediatric acute lymphoblastic leukemia (ALL), the most prevalent cancer among children.
This designation makes SLS009 eligible for a Priority Review Voucher (PRV) upon marketing approval, which can be sold,...

$Sellas Life Sciences(SLS.US)$  whats everyones thought on this.
that drop hurt, but uptrend looks together still.

$Sellas Life Sciences(SLS.US)$
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
SELLAS Life Sciences (NASDAQ: SLS) announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 REGAL trial in acute myeloid leukemia (AML). The IDMC advised the trial to continue without modifications, citing no safety or futility concerns. The IDMC's review of un...